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Abstract
Histidinaemia is a relatively common inherited metabolic disorder with an incidence similar to phenylketonuria. This paper reports the long term outcome of patients diagnosed by newborn screening in the north west of England. Between 1966 and 1990, 108 infants were diagnosed as having histidinaemia by a regional neonatal screening programme We have undertaken a prospective study in 104 patients with histidinaemia over a 28 year period to determine the impact of histidinaemia on their growth, development, and health, and to establish whether there was any benefit from a low histidine diet given for the first 2 years of life.
Methods
All children diagnosed as having histidinaemia by the Willink Biochemical Genetics Unit between 1966 and 1990 were entered into this study. Most of these were first detected by our newborn amino acid screening programme using paper chromatography. The diagnosis of histidinaemia was based on finding persistently raised plasma histidine concentrations (>0 3 mmol/l) and on the presence of histidine and urine imidazole metabolites in the urine.
LOW HISTIDINE DIET
Until 1981, given the uncertainty of the outcome of the disorder and with the possibility that mental retardation might be linked to high blood histidine levels, this unit's policy was to start patients who were diagnosed on newborn screening on a low histidine diet. The main protein requirement was provided by a synthetic food substitute which was histidine-free (for example, HF2, Cow & Gate), while the daily histidine allowance (225 mglkg/d) was given either in the form of cow's milk or, after weaning, in exchange portions of certain vegetables or cereals. The diet was usually discontinued after the age of 2 years. After 1981 this policy was abandoned and newborn infants were allowed a normal diet.
GROWTH, DEVELOPMENT AND GENERAL

HEALTH
Following diagnosis, patients were seen regularly in our clinic where their growth, general health, and development were monitored. Griffiths developmental assessments were performed at 1, 2, 4, and 6 years, and WISC-R intelligence assessments at 8, 12, and 18 years.
PLASMA HISTIDINE CONCENTRATIONS
Plasma histidine concentrations were measured by amino acid analyser (Waters HPLC system using a lithium cation exchange column, Pickering Laboratories). Measurements were made once or twice yearly, except in children on a low histidine diet in the first 2 years of life, where they were made every 3 months. Standard statistical methods were used to compare the data from the intellectual assessments at the various ages with the histidine levels obtained at diagnosis and at the age of testing. In order to compare intellectual performance in histidinaemia patients with that of the general population, IQ scores, obtained from the age of 8 years onwards, were converted to standard deviation scores (SDS) to account for the rise in IQ norms with time. ' 913 infants were screened by the Willink Biochemical Genetics Unit. Histidinaemia was diagnosed in 108 infants, an incidence of 1: 11 083. An additional five children were identified following the diagnosis in a sibling on newborn screening. Nine of these 113 patients either moved away from the region or failed to return to the clinic after the initial diagnosis, so were excluded from this study, leaving a total of 104 children, of whom 51 were female and 53 male. The mean age at diagnosis of those patients detected by newborn screening was 11 days (range 9-18). Forty seven patients were placed on a low histidine diet for an average period of 21 (4 5) months.
PLASMA HISTIDINE CONCENTRATIONS Figure 1 shows the mean plasma histidine concentrations from the time of diagnosis. The histidine concentration at diagnosis was significantly higher in those born before 1981, and who were subsequently treated with a low histidine diet (treated group), than in those begun on a normal diet (non-treated group): 1 29 (0-58) v 0-61 (0 22) mmol/, p<0001.
Following the institution of a low histidine diet in the treated group, the mean plasma histidine concentration was maintained at a significantly lower level than that of the nontreated group [0 3 (0 19) v 0 59 (0 23) mmol/l, p<0 001], although histidine concentrations were still much higher than those of the normal population (0.061-0.119 mmol/l). After the diet was stopped, the mean plasma concentration for the treated group rose to 0-52 (0 23) mmol/l, comparable to that of the untreated group (p=0 55).
GROWTH
Mean weight and height were normal for patients at all ages when compared with Tanner and Whitehouse growth charts. There was no statistical significance between the two dietary groups (figs 2-5).
GENERAL HEALTH
We were unable to identify any increased problems in the general health of either group. Two patients had mild asthma, one had an age related behavioural disorder, and one had mild hyperactivity. Only one patient (from the non-diet group) had significant speech delay. This was more likely to have been due to middle ear disease than to histidinaemia, since following tonsillectomy, adenoidectomy, and treatment at a language unit, he was discharged as normal. Age (years) Figure S The mean height offemale patients plotted on Tanner and Whitehouse growth charts (97th, 50th, and 3rd centiles). Error bars=SD. There was no significant difference between the two dietary groups. The gene for histidase has been mapped to chromosome 1OC2-D1 in mice and 12q22-q24. 1 in humans.23 Although a single mutation has been identified as responsible for murine histidinaemia,24 it is likely that, as with phenylketonuria, several different mutations give rise to human histidinaemia. It is possible that certain of these might be associated with symptoms. This, however, seems unlikely, since in our study we were unable to show any correlation between the level of plasma histidine and any particular clinical problems.
As in the study of Widhalm and Virmani,13
we found no benefit from treatment with a low histidine diet. The general health and growth ofpatients, whether or not on diet, was entirely within the normal range. Analyses comparing histidine levels at the time of diagnosis with IQ or DQ at various ages showed no correlation. Nor was there any significant difference in intellectual performance between the treated and non-treated groups at any age. Finally, we did not find speech impairment to be a problem in our patients.
We conclude that there is no evidence that histidinaemia is detrimental to growth, health, or intellectual development, or that treatment with a histidine restricted diet in the first years of life confers any benefit for intellectual development. Histidinaemia should be considered a benign condition.
